Most clinical trials for COVID-19 are based in higher-income country acute care hospitals (COVID-19 Trial Tracker). Many of these trials exclude marginalized populations, such as people with severe malnutrition, people living with HIV (PLHIV) and people with active or latent tuberculosis (TB).
The goal of the TOGETHER trial is to determine the effectiveness and safety of the initial treatments of high-risk adults within 48 hours of being diagnosed with SARS-CoV-2 infection, who are not requiring hospitalization. This trial uses a novel adaptive platform design.
This trial is based in Brazil and South Africa and will focus on four treatment arms against a placebo arm.
*Total patients randomized
*Total active sites
*Total active treatment arms
Belo Horizonte, Brazil
Cape Town, South Africa
Concurrent with all sites, we will work together to generate comparative data. Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. The TOGETHER Trial team will constantly review information on new drugs and include promising ones in the trial.
This trial is supported with seed funding from the Bill and Melinda Gates Foundation.